BioCentury | Nov 14, 2020
Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

...a handful of liver diseases. 5AM Ventures and Wu Capital...
...$43 millionInvestors: Frazier Healthcare Partners, 5AM Ventures, Wu Capital...
...– Hydroxysteroid 17-beta dehydrogenase 13 Danielle Golovin Inipharm Inc. 5AM Ventures Wu Capital Frazier...
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...$121 million already held by the SPAC. Existing shareholders OrbiMed Advisors, Atlas Venture, Lightstone and Wu Capital...
BioCentury | Sep 10, 2020
Finance

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

...to treat repeat expansion disorders, and was founding CEO of CRISPR company Intellia Therapeutics Inc. (NASDAQ:NTLA). Wu Capital...
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...investors Eight Roads, F-Prime Capital and Vivo Capital were joined by 3H Health Investment and Wu Capital...
BioCentury | Mar 4, 2020
Finance

March 3 Quick Takes: Megarounds for Akouos, Element; plus venture rounds by Kahr, Primmune, Lipidio and Scipio and more

...Investments, EcoR1 Capital, Fidelity Management & Research Co., Polaris Founders Fund, Pagsgroup, Surveyor Capital and Wu Capital...
BioCentury | Jan 11, 2020
Financial News

Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

...are Canaan Partners, AbbVie Ventures, Casdin Capital, DROIA, Foresite Capital, Invus, Pontifax, Taiho Ventures and Wu Capital. Karen...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...Partners, AbbVie Ventures, Casdin Capital, DROIA Oncology Ventures, Foresite Capital, Invus, Pontifax, Taiho Ventures and Wu Capital...
BioCentury | Jun 29, 2018
Product R&D

Highly personal

...GV. Canaan Partners, AbbVie Ventures, Casdin Capital, DROIA, Foresite Capital, Invus, Pontifax, Taiho Ventures and Wu Capital...
BioCentury | Dec 1, 2017
Finance

Semma prepares to deliver

...led the B round, which closed on Nov. 30. Fellow new investors ORI Healthcare Fund, Wu Capital...
BioCentury | Nov 30, 2017
Financial News

Regenerative medicines play Semma raises $114M

...led by Eight Roads Ventures and Cowen Healthcare Investments. Fellow new investors ORI Healthcare Fund, Wu Capital...
Items per page:
1 - 10 of 10
BioCentury | Nov 14, 2020
Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

...a handful of liver diseases. 5AM Ventures and Wu Capital...
...$43 millionInvestors: Frazier Healthcare Partners, 5AM Ventures, Wu Capital...
...– Hydroxysteroid 17-beta dehydrogenase 13 Danielle Golovin Inipharm Inc. 5AM Ventures Wu Capital Frazier...
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...$121 million already held by the SPAC. Existing shareholders OrbiMed Advisors, Atlas Venture, Lightstone and Wu Capital...
BioCentury | Sep 10, 2020
Finance

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

...to treat repeat expansion disorders, and was founding CEO of CRISPR company Intellia Therapeutics Inc. (NASDAQ:NTLA). Wu Capital...
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...investors Eight Roads, F-Prime Capital and Vivo Capital were joined by 3H Health Investment and Wu Capital...
BioCentury | Mar 4, 2020
Finance

March 3 Quick Takes: Megarounds for Akouos, Element; plus venture rounds by Kahr, Primmune, Lipidio and Scipio and more

...Investments, EcoR1 Capital, Fidelity Management & Research Co., Polaris Founders Fund, Pagsgroup, Surveyor Capital and Wu Capital...
BioCentury | Jan 11, 2020
Financial News

Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

...are Canaan Partners, AbbVie Ventures, Casdin Capital, DROIA, Foresite Capital, Invus, Pontifax, Taiho Ventures and Wu Capital. Karen...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...Partners, AbbVie Ventures, Casdin Capital, DROIA Oncology Ventures, Foresite Capital, Invus, Pontifax, Taiho Ventures and Wu Capital...
BioCentury | Jun 29, 2018
Product R&D

Highly personal

...GV. Canaan Partners, AbbVie Ventures, Casdin Capital, DROIA, Foresite Capital, Invus, Pontifax, Taiho Ventures and Wu Capital...
BioCentury | Dec 1, 2017
Finance

Semma prepares to deliver

...led the B round, which closed on Nov. 30. Fellow new investors ORI Healthcare Fund, Wu Capital...
BioCentury | Nov 30, 2017
Financial News

Regenerative medicines play Semma raises $114M

...led by Eight Roads Ventures and Cowen Healthcare Investments. Fellow new investors ORI Healthcare Fund, Wu Capital...
Items per page:
1 - 10 of 10